Stonepine Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

Stonepine Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.71M	Sell	258,701 -221,299	-46%	-$2.46M	2.09%	17
2026 Q1	$4.47M	Sell	480,000 -89,088	-16%	-$803K	1.79%	11
2025 Q4	$5.1M	Sell	569,088 -240,912	-30%	-$2.28M	3.72%	4
2025 Q3	$7.7M	Buy	810,000 +34,380	+4%	+$345K	6.26%	4
2025 Q2	$6.83M	Buy	775,620 +125,620	+19%	+$1.02M	6.7%	3
2025 Q1	$4.87M	Buy	650,000 +52,300	+9%	+$416K	4.74%	4
2024 Q4	$4.98M	Sell	597,700 -102,300	-15%	-$873K	4.02%	5
2024 Q3	$4.86M	Buy	+700,000	New	+$4.75M	3.07%	8

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Stonepine Capital Management's ZVRA Position: Q2 2026 in Review

Stonepine Capital Management reduced its Zevra Therapeutics (ZVRA) stake by 46% in Q2 2026, selling an estimated $2.46M and leaving 258,701 shares worth $3.71M. The position accounts for 2.09% of the portfolio, ranked #17.

Stonepine Capital Management first reported a position in ZVRA in Q3 2024 and has held it in 8 quarters since. The position peaked at $7.7M in Q3 2025. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

Stonepine Capital Management held 258,701 shares of Zevra Therapeutics worth $3.71M as of Q2 2026.
Stonepine Capital Management sold 221,299 Zevra Therapeutics shares in Q2 2026, an estimated $2.46M.
Zevra Therapeutics made up 2.09% of Stonepine Capital Management's portfolio in Q2 2026, its #17 holding.
Stonepine Capital Management first reported a position in Zevra Therapeutics in Q3 2024 and has held it in 8 quarters since.
Stonepine Capital Management's Zevra Therapeutics position peaked at $7.7M in Q3 2025.
157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.